北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 淋巴肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma
作者: Fu, Zhiying; Zhu, Jun; Zheng, Wen; Liu, Weiping; Ying, Zhitao; Xie, Yan; Wang, Xiaopei; Lin, Ningjing; Tu, Meifeng; Ping, Lingyan; Deng, Lijuan; Zhang, Chen; Ding, Ning; Song, Yuqin
关键词: Bevacizumab ; DLBCL ; Safety ; Efficacy
刊名: CANCER CELL INTERNATIONAL
发表日期: 2014-01-18
DOI: 10.1186/1475-2867-14-5
卷: 14
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: CARDIOVASCULAR TOXICITY ; CANCER-PATIENTS ; RITUXIMAB ; TRIAL ; CHEMOTHERAPY ; METAANALYSIS ; MECHANISMS ; THERAPY ; RISK
英文摘要:

Background: Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma (DLBCL), a common sub-type of non-Hodgkin lymphoma. But 40% - 50% of DLBCL patients cannot be cured by this regimen. Some clinical trials showed that bevacizumab might be useful in the treatment of DLBCL. This study evaluated the safety and efficacy of bevacizumab combined with the R-CHOP (A-R-CHOP) regimen in Chinese patients with previously untreated DLBCL.

Methods: Patients with previously untreated DLBCL received A-R-CHOP regimen therapy. All patients with complete response (CR)/unconfirmed complete response(CRu) after 8 cycles of A-R-CHOP received the bevacizumab maintenance therapy once every 3 weeks. The remained bulky disease was treated with radiotherapy.

Results: Seven Chinese patients were treated. All of them had bulky diseases. One patient had progressive disease after 4 cycles of A-R-CHOP therapy. The rest six patients completed 8 cycles of A-R-CHOP treatment. All of these six patients reached CR/CRu (5 CR, 1 CRu). Bevacizumab maintenance therapy was given to 4 CR patients. All 7 patients experienced Grade 3/4 hematologic adverse events; additionally, one had Grade 3 gastrointestinal toxicity and one had Grade 1 epistaxis. During bevacizumab maintenance therapy, one patient had Grade 1 gingival bleeding, another experienced Grade 1 proteinuria and then Grade 3 congestive heart failure 4 months after completion of maintenance therapy. At the end of July 2013, the patient who had progressive disease after 4 cycles of A-R-CHOP died of progressive disease, the other six remained CR response.

Conclusions: The A-R-CHOP regimen is effective for untreated DLBCL, but may cause bevacizumab-specific toxicities, which should be monitored.

语种: 英语
WOS记录号: WOS:000334613500001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/61794
Appears in Collections:北京大学临床肿瘤学院_淋巴肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China

Recommended Citation:
Fu, Zhiying,Zhu, Jun,Zheng, Wen,et al. Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma[J]. CANCER CELL INTERNATIONAL,2014,14.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Fu, Zhiying]'s Articles
[Zhu, Jun]'s Articles
[Zheng, Wen]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Fu, Zhiying]‘s Articles
[Zhu, Jun]‘s Articles
[Zheng, Wen]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace